Parabilis Medicines
Cambridge
About Parabilis Medicines
Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced a novel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Total funding: $835.3M
- Funding stage: Late Stage Venture
- Last round: Series F (Jan 2026)
- Website: parabilismed.com
- Phone: +1 617-945-9510
Industries & Categories
Biopharma, Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/parabilis-medicines-2164 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.